Recall of clinical trial participation and attrition rates in survivors of acute respiratory distress syndrome

J Crit Care. 2021 Aug;64:160-164. doi: 10.1016/j.jcrc.2021.04.006. Epub 2021 Apr 17.


Purpose: To measure the rate of recall of study participation and study attrition in survivors of acute respiratory distress syndrome(ARDS).

Materials/methods: In this ancillary study of the Re-evaluation of Systemic Early neuromuscular blockade(ROSE) trial, we measured the rate of study participation recall 3 months following discharge and subsequent study attrition at 6 months. We compared patient and hospital characteristics, and long-term outcomes by recall. As surrogate decision-makers provided initial consent, we measured the rate of patient reconsent and its association with study recall.

Results: Of 487 patients evaluated, recall status was determined in 386(82.7%). Among these, 287(74.4%) patients recalled participation in the ROSE trial, while 99(25.6%) did not. There was no significant difference in 6-month attrition among patients who recalled study participation (9.1%) and those who did not (12.1%) (p = 0.38). Patient characteristics were similar between groups, except SOFA scores, ventilator-free days, and length of stay. 330(68%) were reconsented. Compared to those not reconsented, significantly more patients who were reconsented recalled study participation(78% vs. 66%;p = 0.01).

Conclusions: One in 4 ARDS survivors do not recall their participation in a clinical trial during hospitalization 3 months following hospital discharge, which did not influence 6-month attrition. However, more patients recall study participation if reconsent is obtained.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Clinical Trials as Topic
  • Humans
  • Mental Recall
  • Patient Discharge
  • Respiratory Distress Syndrome* / therapy
  • Survivors* / psychology